



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

September 14, 2023

Henry O. Gosebruch  
Chief Executive Officer  
Neumora Therapeutics, Inc.  
490 Arsenal Way, Suite 200  
Watertown, Massachusetts 02472

**Re: Neumora Therapeutics, Inc.**  
**Amendment No. 1 to Registration Statement on Form S-1**  
**Exhibit Nos. 2.1, 2.2, 10.2, 10.3, 10.4, 10.5(a), 10.5(c), 10.14(a) and 10.14(b)**  
**Filed September 11, 2023**  
**File No. 333-274229**

Dear Henry O. Gosebruch:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance